PFE

Pfizer develops and manufactures prescription medicines, vaccines, and consumer healthcare products across oncology, internal medicine, vaccines, inflammation, and rare diseases. The company's COVID-19 franchise generated $56 billion in peak revenues, creating a massive cash pile that's now funding an aggressive oncology expansion through acquisitions like Seagen's $43 billion purchase. Management expects the oncology portfolio to drive $25 billion in annual revenues by 2030, replacing declining COVID sales with higher-margin, patent-protected cancer treatments. Trading at 9.4x forward earnings with a 6% dividend yield, shares price in the COVID revenue cliff while overlooking the transformation into a oncology-focused growth story.